inv(16)(p13q22) CBFB/MYH11 in treatment related leukemia

2003-10-01   Jean-Loup Huret  

1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Clinics and Pathology

Disease

Treatment related myelodysplasia (t-MDS) or acute myeloid leukaemias (t-AML)

Note

The study included 48 cases; t-MDS without progression to AML accounted for 8%, t-MDS with progression to AML for 13% and t-AML for the remaining 79% the AML subtype was M4eo in 83%, M2 in 14%; no case of acute lymphoblastic leukaemia

Epidemiology

inv(16)(p13q22) was found in 9% of t-MDS/t-AML; sex ratio: 18M/30F

Clinics

Age at diagnosis of the primary disease 43 yrs (range 6-75); age at diagnosis of the t-MDS/t-AML: 48 yrs (range 13-77). Median interval was short: 22 mths (range: 8-533). Primary disease was a solid tumor in 71% of cases (in particular breast cancer, sarcoma, cancer of the ovary) and a hematologic malignancy in 27%, treatment was radiotherapy (21%, a relatively high proportion compared to other groups), chemotherapy (29%), or both (50%). Treatment included topoisomerase II inhibitors in 60% of cases and alkylating agents in 63%.

Prognosis

Patients under 55 yrs of age had better outcome. Median survival was 29 mths, with 45% of patients surviving at 5 yrs, the best survival among subgroups of treatment related leukemias with a balanced chromosome aberration (patients with 11q23 rearrangement, 3q21q26 rearrangement, 12p13 rearrangement, t(9;22), t(8;16), or a 21q22 rearangement)). Patients with t(15;17) had similar median survival, but less long term survivors.

Genes Involved and Proteins

Result of the Chromosomal Anomaly

Description

5CBFB -3¹ MYH11

Highly cited references

Pubmed IDYearTitleCitations
318179112019Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription.150
344401572021How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring.123
380610172023Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia-initiating CBFB::MYH11 oncofusion protein.112
328312962020CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia.93
368743782023Therapy-related core binding factor acute myeloid leukemia.86
297559562018Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia.81
348044412021Gastrointestinal Myeloid Sarcoma a Case Presentation and Review of the Literature.80
277986252016The genomic landscape of core-binding factor acute myeloid leukemias.79
407633102025CBFβ-SMMHC-driven leukemogenesis requires enhanced RUNX1-DNA binding affinity in mice.72
370199722023Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication.71
346866642021Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance.70
343368312021CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML.67
429338902026CBFB-MYH11 directly activates TGFβ and PD-L1 to drive immune evasion in acute myeloid leukemia.66
337308432022Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia.54
408291682025Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.52
359739832022Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia.52
338365812021Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells.51
389369132024Molecular and Clinical Insights in the Increasing Detection of BCR::ABL1 p190+ in Adult Acute Myeloid Leukemia Patients.50
401564262025The Fusion Genes and Their Relation with Genetic Variants in Egyptian AML Patients.48
364420872022Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia.47
329294732020RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.47
316243762020Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice.46
399661222025Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia.45
307420532019IL1RL1 is dynamically expressed on Cbfb-MYH11(+) leukemia stem cells and promotes cell survival.43
352511312022Fusion Gene Detection Using Whole-Exome Sequencing Data in Cancer Patients.43
412946672025Unveiling the Genetic Mosaic of Pediatric AML: Insights from Southwest China.43
376990012023Rapid detection of myeloid neoplasm fusions using single-molecule long-read sequencing.42
347715192021CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management.42
290180802017Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11.41
318967822020The clinical mutatome of core binding factor leukemia.40
413007352025CBFB::MYH11 Fusion Located on a Supernumerary Ring Chromosome 16 in Pediatric Acute Myeloid Leukemia: Diagnostic Challenges and Prognostic Implications.39
357945672022Molecular dissection of a hyper-aggressive CBFB-MYH11/FLT3-ITD-positive acute myeloid leukemia.37
345477722021CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes.35
411732052026Cohesin haploinsufficiency is tolerated in Cbfb::MYH11-driven murine acute myeloid leukemia.35
384932002024Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies.34
369394022023Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study.33
403040772025Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia.33
354979382022Therapy-related acute myeloid leukemia: A case series.30
390205342024Classic and molecular cytogenetic findings in leukemia patients from the Western part of Romania.23
346602932021Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia.20
204214542010Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins.19
425330042026Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine.15
372259652023Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing.14
338161052021Primary peritoneal myeloid sarcoma in association with CBFB/MYH11 fusion.13
411529852025Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution.13
375916212023Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications.11
222284032012Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.10
345129852021Abnormal eosinophils with immature eosinophilic granules in chronic myeloid leukemia in accelerated phase.2
381537682023CBFB::MYH11 fusion in a nonmonocytic acute myeloid leukemia.0
220325822011Core-binding factor acute myeloid leukemia.0
356220052022AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome.0
322022502021Detection of del(16q) using the CBFB-MYH11 translocation dual fusion probe.0
366536962023Comprehensive molecular understanding of pediatric acute myeloid leukemia.0
192159832009Aleukemic bcr-abl positive granulocytic sarcoma.0
331625102020[Clinical significance of MRD in AML].0
360390182022Mutual exclusivity between the fusion gene CBFB::MYH11 and somatic mitochondrial mutations in acute myeloid leukaemia.0
409310472025Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.0
345465432022All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16.0
282996612017Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.0
383887942024Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.0
421355162026CBFB::MYH11 MRD after the second chemotherapy cycle: a guide for allogeneic transplantation in favorable-risk AML.0
371023022023TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia.0
316714342020Myeloid Sarcoma With CBFB-MYH11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen.0
326523282020IL-33/IL1RL1 axis regulates cell survival through the p38 MAPK pathway in acute myeloid leukemia.0
399059352025Clonal dynamics of chronic myelomonocytic leukemia progression: paired-sample comparison.0
351286342022TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event.0
240025882014CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.0
341837802021Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11.0
316124662020Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup.0
419669162026SOHO State of the Art Updates and Next Questions: Is Favorable-risk AML Always Favorable?0
300062582018Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.0
268918772016Leukemogenic potency of the novel FLT3-N676K mutant.0
87514661996The gene product of CBFB-MYH11.0
256357582015Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.0
346749822022Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype.0
402933512025Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia.0
313531652020Detection of a novel CBFB-MYH11 fusion transcript in acute myeloid leukemia M1 with inv(16)(p13q22).0
384471912024A Case of a Patient with Therapy-related Core Binding Factor (CBF) Acute Myeloid Leukemia (CBF-AML).0
398035622024Loss of the Inv(16) Oncogene CBFB::MYH11 Eliminates Leukemia from the Blood and Spleen, but not the Bone Marrow.0
309195052019Measurable residual disease testing for personalized treatment of acute myeloid leukemia.0
282996582017Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.0
306953132016[Case Conference of Hematological Malignancies Based on the Morphology of Blood Cells: Chairmen's Introductory Remarks].0
211982992010Incidence and prognostic importance of molecular genetic defects in children with acute myeloblastic leukemia.0
289060042017Acute myeloid leukaemia (FAB AML-M4Eo) with cryptic insertion of cbfb resulting in cbfb-Myh11 fusion.0
324920022020[Driver Mutations in Acute Myeloid Leukemia with Inversion of Chromosome 16].0
287354862017Detection and Quantification of Acute Myeloid Leukemia-Associated Fusion Transcripts.0
355317602022Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.0
122391552002Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11.0
274688692016Incidence of preleukemic fusion genes in healthy subjects.0
391826712024Tailored Digital PCR Follow-Up of Rare Fusion Transcripts after Initial Detection through RNA Sequencing in Hematological Malignancies.0
115611562001Function of the inv(16) fusion gene CBFB-MYH11.0
411392312025Optimizing Wilms tumor 1 thresholds for measurable residual disease monitoring in acute myeloid leukemia: Improved sensitivity and concordance with nucleophosmin 1 in a single-center validation study.0
121725392002Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis.0
346746152021Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.0
396591452025Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial.0
302771152019Panoramic view of common fusion genes in a large cohort of Chinese de novo acute myeloid leukemia patients.0
412508752026Genomic and transcriptomic characterization of acute myeloid leukaemia with IL3RA overexpression: Prognostic and therapeutic implications revisited.0
86304301996Novel CBFB-MYH11 fusion transcripts or reverse transcription-polymerase chain reaction artifacts?0
75776151995Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission.0
380845512023Therapy-related acute myeloid leukemia with CBFB/MYH11 in a patient with ovarian cancer after exposure to chemotherapy.0

Article Bibliography

Pubmed IDLast YearTitleAuthors
119212732002Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop.Andersen MK et al

Summary

Fusion gene

CBFB/MYH11 CBFB (16q22.1) MYH11 (16p13.11) M ins(16)(q22p13p13) ins(16;16)(q22;p13p13) inv(16)(p13q22) t(16;16)(p13;q22)|CBFB/MYH11 CBFB (16q22.1) MYH11 (16p13.11) TIC

Note

This data is extracted from a very large study from an International Workshop on treatment related leukemias - restricted to balanced chromosome aberrations (i.e.: -5/del(5q)and -7/del(7q) not taken into account per see), published in Genes,Chromosomes and Cancer in 2002.
Atlas Image
inv(16)(p13q22) CBFB/MYH11  and t(16;16)(p13;q22) CBFB/MYH11 Top: inv(16) FISH and diagram - Courtesy Hossein Mossafa; Middle Left: first row: inv(16)(p13q22) G-banding - Courtesy Diane H. Norback, Eric B. Johnson, and Sara Morrison-Delap, UW Cytogenetic Services; second row - Courtesy Hossein Mossafa; Middle Right: t(16;16)(p13;q22) u2013 Courtesy Adriana Zamecnikova; Bottom: Fluorescence in situ hybridization with the Vysis LSI CBFB break apart probe (Abbott Molecular, US) showing disruption of the gene as a result of (A) inv(16) and (B) its translocation to der(16) as a result of t(16;16) u2013 Courtesy Adriana Zamecnikova - Courtesy Adriana Zamecnikova.

Citation

Jean-Loup Huret

inv(16)(p13q22) CBFB/MYH11 in treatment related leukemia

Atlas Genet Cytogenet Oncol Haematol. 2003-10-01

Online version: http://atlasgeneticsoncology.org/haematological/1297/inv(16)(p13q22)